Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...

Camcevi ETM, a long-acting injectable, is FDA-approved for advanced prostate cancer, showing 97.9% efficacy in testosterone suppression in a phase 3 study. Common side effects include hot flushing and ...

Prostate cancer is the second most common cancer diagnosis in men. 1 in 8 men will be diagnosed with the disease during their lifetime. Dr. Jose Avita from the New Mexico Cancer Center talked about ...

Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...

PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– ...